[Ip-health] Launch : "Observatoire de la transparence dans les politiques du médicaments"
advocacy at canceralliance.co.za
Thu Jun 13 00:35:20 PDT 2019
Well done Pauline for this initiative!
It may inspire all of us to work on this - perhaps set some key objectives
with timelines. Would be wonderful if all communication could be translated
as well in English so that we can share as best practice.
Project manager: Access to Medicine campaign
Mobile l +27 079 483 3175
Work l + 27 021689 1942
Skype l salomemeyer
Twitter l @Cancer_ZA
Facebook l Salomé Meyer
On Thu, 13 Jun 2019 at 09:25, Pauline Londeix <pauline.londeix at gmail.com>
> [Apologizes for cross-posting]
> Dear colleagues and friends,
> I am thrilled to share with you the announcement of the launch of the
> "Observatoire de la transparence dans les politiques du médicaments"
> (https://twitter.com/OTMeds), an organization based in France to
> monitor the implementation of the WHO transparency resolution in
> France. The resolution that was adopted by the World Health Assembly
> in May 2019, calls on countries to implement transparency on medicines
> prices. The French government also showed its support to this initial
> text proposed for the resolution going further than prices, and we now
> want full transparency to be implemented in France.
> Transparency is critical for countries like France to face the
> unstoppable increases in medicines prices and to sustain their health
> Besides monitoring the advancement on the implementation of the
> transparency resolution in pricing, clinical trials, research and
> development, marketing and patenting, the Observatory will also
> monitor the position of France within the international institutions
> (WIPO, WTO, WHO, etc), as well as at the European level, in particular
> as part of the European Commission (EC) negotiating Free Trade
> agreements such as MERCOSUR, Tunisia and Morocco. These agreements
> currently in negotiation include, on the request of the EC, provisions
> such as data exclusivity and trade secrets, that go in the opposite
> direction to transparency.
> While high medicines' prices jeopardize the sustainability of our
> public health systems and also delay access to many new medicines,
> they also put many life-saving medicines out of reach of millions in
> low and middle income countries. Medicines are developed thanks to a
> large contributions from taxpayers. It is unjust that the benefits are
> only private. We believe that it is time for public interests to
> prevail on corporations' interests and to change the narrative. These
> are our drugs !
> The observatory will work hand in hand with local and international
> NGO partners.
> Best regards,
> Pauline Londeix
> You received this message because you are subscribed to the Google Groups
> "Access to Medicines & Innovation" group.
> To unsubscribe from this group and stop receiving emails from it, send an
> email to accesstomedsandinnovation+unsubscribe at googlegroups.com.
> To post to this group, send email to
> accesstomedsandinnovation at googlegroups.com.
> To view this discussion on the web visit
> For more options, visit https://groups.google.com/d/optout.
More information about the Ip-health